Forbes, I agree with you GSK has been forced to increase Relenza production. If not for the idiotic Peter Cook and his mates, I believe a credible management would force GSK into producing a lot more than the planned 60million courses per annum. I also agree with you that the Relenza royalty stream is driven by the market demand and has nothing to do with GSK or BTA management which is why it is utmost disgusting for Peter Cook to claim credit for the increase in Relenza sales and to see some of the blatantly dishonest posts here praising the idiotic Peter Cook.
However GSK has not been forced into making a new delivery method. By the time the new delivery method is approved by regulatory authorities, BTA patents will be expiring – take a guess who owns the new patents for the new delivery method? Yes, Forbes, it is not BTA. The only good thing for BTA shareholders is that LANI will supersedes Relenza and Tamiflu.
BTA Price at posting:
$1.19 Sentiment: None Disclosure: Not Held
